Immunophotonics was recently granted approval by the NIH’s National Cancer Institute to transition from Phase I to Phase II Fast-track grant from Small Business Innovative Research (SBIR) for research regarding use of the company’s lead drug candidate, IP-001, in nonclinical models of Hepatocellular Carcinoma (HCC) in conjunction with thermal tumor ablation by microwave. This research...
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at Hôpital Foch in Suresnes. The protocol has been approved within the United States, United Kingdom, Switzerland, France, and Germany and will have over a dozen sites participating. The principal objective of this study is to...
Immunophotonics Co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Boston attending the RESI Boston 2023, September 18th, at Boston Park Plaza.
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be at Booth F18 at the CIRSE 2023 Conference, September 9 – 13 in Copenhagen, Denmark. They are excited to discuss how Immunophotonics is advancing the novel concept of abscopalizing routine tumor destruction procedures.
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in Germany at SLK Kliniken Heilbronn GmbH. The patient was treated as part of a multinational clinical trial sponsored by Immunophotonics (IP-IIO-622) that will assess the safety and efficacy of its lead asset, IP-001. The protocol has been approved by regulatory authorities in...
Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the United Kingdom at the University College London. This multinational clinical trial sponsored by Immunophotonics will assess the safety and efficacy of its lead asset, IP-001, and is currently enrolling patients for treatment of colorectal cancer,...
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th Annual Immuno-Oncology Innovation Forum, June 2, and the ASCO (American Society of Clinical Oncology) annual meeting, June 2 – 6. They will be connecting with investors and clinical experts to discuss how Immunophotonics continues to...
Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of patients based on the company’s investigational new drug (IND) application. This extends the company’s INJECTABL-1 trial to the treatment of metastatic colorectal cancer, lung cancer, and sarcoma patients in the USA. Read more (Official Press...
Immunophotonics is pleased to announce its participation at the Swiss Biotech Day in Basel, Switzerland where VP of Business Development Theresa Visarius will present initial clinical and translational data on the use of IP-001 in solid tumor indications on April 24th in the Clinical Stage Development Companies session.
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Booth 10 at the European Conference on Interventional Oncology (ECIO 2023) in Stockholm, Sweden, on April 16 – 19. They are looking forward to connecting with clinical experts and learning from their experiences, as well as discussing how Immunophotonics continues...
